StockData
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.91−0.24 (-20.87%)

Close on Nov 18, 2026Market cap $19.92MP/E –Yield –

Aardvark Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Aardvark Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $0. For fiscal 2025 it was $0.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0–
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0–

More Aardvark Therapeutics figures

See a number that looks wrong?